Bayer's Balancing Act: Job Cuts and Legal Peril Amid a Wall Street Rebound

Bayer cuts 14,000 jobs to slash debt as Wall Street turns bullish. A critical AGM and Supreme Court case on glyphosate will shape its future amid financial strain.

As Bayer approaches a pivotal shareholder meeting, the German conglomerate presents a starkly divided picture. While CEO Bill Anderson presides over a drastic corporate restructuring involving thousands of job cuts, a wave of optimism is building among financial analysts in New York. This contrast defines a critical fortnight for the company, marked by legal uncertainty and a quiet period in investor communications.

The scale of Anderson’s turnaround effort is substantial. Since the strategic overhaul began, approximately 14,000 positions have been eliminated, with 4,700 of those cuts occurring in the past year alone. The CEO has signaled that further significant measures are on the horizon in the coming months. The primary goal remains clear: reducing the company's massive debt pile, which saw its net financial debt decrease by 8.5% to just under 30 billion euros in the 2025 fiscal year.

This operational push coincides with a notable shift in sentiment on Wall Street. Goldman Sachs recently reaffirmed its buy rating on Bayer shares, raising its price target to 55 euros. Analyst James Quigley anticipates that the upcoming first-quarter figures, due on May 12, could surpass current market expectations. The stock, currently trading around 41 euros, has already staged a remarkable 91% recovery over a twelve-month horizon, though it remains about 16% below its 52-week high of 49.17 euros.

Investor attention now splits between two immediate events. On Friday, April 24, Bayer holds its virtual Annual General Meeting. The agenda includes supervisory board appointments, with Marcel Smits, former Chairman and CEO for Cargill's Asia-Pacific region, standing as a candidate. Shareholders will also approve a maintained dividend of 0.11 euros per share, payable on April 29. More critically, the following Monday sees oral arguments begin in the Durnell case before the U.S. Supreme Court—a proceeding that will heavily influence the long-term risk assessment of Bayer's agricultural division and its ongoing glyphosate litigation.

The financial results for 2025 underscore the company's challenging position. While currency-adjusted sales grew 1.1% to approximately 45.6 billion euros, special expenses from legal disputes exceeding 6 billion euros caused free cash flow to plummet by nearly a third to around 2.1 billion euros. Looking ahead to 2026, Bayer forecasts sales between 45 and 47 billion euros and EBITDA before special items in a range of 9.6 to 10.1 billion euros. However, the company anticipates a negative free cash flow of roughly 5 billion euros due to expected glyphosate settlement payments.

Amid these financial and legal pressures, a subtle positive signal has emerged from sustainability raters. MSCI Solutions awarded Bayer an AA sustainability rating for the first time, while Sustainalytics removed its "Red Flag" status at the end of 2025, citing progress in containing glyphosat risk. For now, with the quiet period in effect, direct communication from Bayer's headquarters is on hold until the investor video call in mid-May, leaving the market to weigh deep restructuring against a fragile, yet growing, sense of hope.